BioMarin UK Limited

BioMarin UK Limited is the United Kingdom branch of BioMarin Pharmaceutical Inc., a global biotechnology company specializing in the development and commercialization of innovative therapies for rare genetic disorders. Founded in 1997 and headquartered in San Rafael, California, BioMarin has established itself as a leader in genetic medicine, focusing on addressing the root causes of genetic conditions through targeted therapies. The company’s research and development efforts have yielded multiple commercial therapies and a robust pipeline of clinical and pre-clinical candidates aimed at significant unmet medical needs. BioMarin’s distinctive approach emphasizes well-understood biology and the potential to be first-to-market or to offer substantial benefits over existing treatments.

BioMarin UK Limited operates within the pharmaceutical wholesale sector in the UK and engages in lobbying activities related to healthcare policy, pharmaceutical regulation, and research funding within the European Union. The company is committed to transparency in its interactions with healthcare professionals and organizations, disclosing transfers of value in accordance with industry standards and regulatory requirements.

Since its incorporation in the UK in December 2009, BioMarin UK Limited has been active in advocating for policies that support innovation in biotechnology and patient access to novel therapies. It collaborates closely with healthcare stakeholders, regulatory bodies, and affiliated organizations to promote the interests of patients with rare diseases and to advance scientific research.

BioMarin’s lobbying efforts are aligned with its broader mission to transform lives through genetic discovery, ensuring that EU legislative and regulatory frameworks facilitate the development and availability of cutting-edge treatments. The company’s transparency reports reveal a structured approach to compliance and ethical engagement, reflecting its dedication to responsible corporate citizenship within the EU policy environment.

Company Name: BioMarin UK Limited
Incorporation Date: 23 December 2009
Company Type: Private Limited Company
Registered Office: 10 Bloomsbury Way, London, WC1A 2SL, United Kingdom
Nature of Business: Wholesale of pharmaceutical goods (SIC 46460)
Parent Company: BioMarin Pharmaceutical Inc., Delaware, USA
EU Transparency Register ID: Available on EU register (specific ID not provided)
Main Activities: Lobbying on pharmaceutical regulation, healthcare policy, research funding, and patient access to therapies

No related lobbyists found.

BioMarin UK Limited’s lobbying activities primarily fall under:

Pharmaceuticals and Biotechnology
Healthcare and Medical Research
Rare Diseases and Genetic Disorders
Research and Development Funding
Regulatory Affairs and Market Access

BioMarin UK Limited networks with various healthcare organizations, patient advocacy groups, scientific associations, and regulatory bodies within the EU. It is affiliated with BioMarin International Limited in Ireland and collaborates with industry groups for transparency and ethical standards in pharmaceutical lobbying. The company also engages with healthcare professionals, decision-makers, and healthcare organizations (HCOs) across Europe to support its research and policy objectives.

BioMarin UK Limited’s exact lobbying expenditure figures since registration are not publicly detailed in the provided search results. However, as a subsidiary of a global biotech firm with reported revenues of $2.4 billion in 2023, it is reasonable to infer that the UK entity’s lobbying budget is part of a broader corporate strategy supporting EU engagement. The EU Transparency Register typically categorizes such expenditures in bands, but specific yearly breakdowns for BioMarin UK Limited are not available in the sources.

BioMarin UK Limited interacts with multiple EU institutions, including:

European Commission (Directorates related to Health and Pharmaceuticals)
European Medicines Agency (EMA)
European Parliament Committees on Environment, Public Health and Food Safety
Council of the European Union (Health Ministers)

These interactions focus on regulatory approvals, pharmaceutical legislation, and research funding frameworks.

Detailed records of meetings held by BioMarin UK Limited with EU institutions since registration are not explicitly available in the search results. Typically, such meetings involve discussions on drug approvals, regulatory compliance, patient access programs, and research collaborations. The EU Transparency Register would hold official logs of these meetings, but no specific entries are cited here.